Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab and Proton Therapy for Recurrent Meningioma
NCT03267836Phase 1Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Jan 2018
- Primary completion
- Apr 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of avelumab in meningioma, sponsored by Washington University School of Medicine. Primary endpoint: Immunogenicity as measured by changes of CD8+/CD4+ tumor infiltrating lymphocytes (TILs). Started Jan 2018; status: terminated.
02
Drugs
avelumab
03
Conditions
meningioma
Beyond the preview
Go deeper on NCT03267836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03267836.